help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on December 4, 2007
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-1902
A more recent version of this article appeared on February 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
93/2/565    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nesterova, M.
Right arrow Articles by Stratakis, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nesterova, M.
Right arrow Articles by Stratakis, C. A.
Related Collections
Right arrow Thyroid
Right arrow Endocrine Oncology

Submitted on August 23, 2007
Accepted on November 27, 2007

An immortalized human cell line bearing a PRKAR1A-inactivating mutation: effects of over-expression of the wild-type allele and other protein kinase A (PKA) subunits

Maria Nesterova*, Feng Wen, Anelia Horvath, Ludmila Matyakhina, and Constantine A. Stratakis

Section on Endocrinology & Genetics, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, MD 20892, USA; Cellular Biochemistry Section, Basic Research Laboratory, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD 20892, USA

* To whom correspondence should be addressed. E-mail: nesterom{at}mail.nih.gov.

Context: Inactivating mutations of PRKAR1A, the regulatory subunit type 1A (RI{alpha}) of protein kinase A (PKA), are associated with tumor formation.

Objective: To evaluate the role of PKA isozymes on proliferation and cell cycle.

Methods: A cell line with RI{alpha} haploinsufficiency due to an inactivating PRKAR1A mutation (IVS2+1 G>A) was transfected with constructs encoding PKA subunits. Genetics, PKA subunit mRNA and protein expression and proliferation, aneuploidy and cell cycle status were assessed. To identify factors that mediate PKA-associated cell cycle changes, we studied E2F and cyclins expression in trasfected cells and E2F's role by siRNA; we also assessed cAMP levels and baseline and stimulated cAMP signaling in transfected cells.

Results: Introduction of PKA subunits led to changes in proliferation and cell cycle: a decrease in aneuploidy and G2/M for the PRKAR1A-transfected cells and an increase in S phase and aneuploidy for cells transfected with PRKAR2B, a known PRKAR1A mutant (RI{alpha}P), and the PKA catalytic subunit. There were alterations in cAMP levels, PKA subunit expression, cyclins and E2F factors; E2F1 was shown to possibly mediate PKA effects on cell cycle by siRNA studies. cAMP levels and constitutive and stimulated cAMP signaling were altered in transfected cells.

Conclusion: This is the first immortalized cell line with a naturally occurring PRKAR1A-inactivating mutation that is associated in vivo with tumor formation. PKA isozyme balance is critical for the control of cAMP signaling and related cell cycle and proliferation changes. Finally, E2F1 may be a factor that mediates dysregulated PKA's effects on the cell cycle.


Key words: Adrenal tumors • Cushing syndrome • protein kinase A • cyclic AMP • tumor suppressor gene







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society